IP Library › Granted Patent US 7,402,656
Granted Patent B2
US 7,402,656 · App. 10/219,472 · Granted Jul 22, 2008

PRO10013 polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,656
App. No.
10/219,472
Granted
Jul 22, 2008
Kind
B2
Abstract

The present invention is directed to novel PRO10013 polypeptides chimeric polypeptide molecules comprising PRO10013 polypeptides fused to heterologous polypeptide sequences.

Claims (8)

1. An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 34; or

(b) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-1096,

wherein said polypeptide is overexpressed in colon tumor cells.

2. The isolated polypeptide of claim 1 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 34.

3. The isolated polypeptide of claim 2 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-1096.

4. A chimeric polypeptide comprising a polypeptide according to claim 1 fused to a heterologous polypeptide.

5. The chimeric polypeptide of claim 4 , wherein said heterologous polypeptide is an epitope tag on an Fc region of an immunoglobulin.